Pharmaceutical giant Zydus Lifesciences has launched a new biosimilar therapy targeting visual impairment, marking a significant advancement in ophthalmic care. The product offers an alternative to existing biologics, promising comparable efficacy at a more accessible cost, potentially reducing treatment expenditures for patients. Analysts view this launch as a strategic move to strengthen Zydus’s presence in the high-growth ophthalmology segment, which is witnessing rising demand due to aging populations and chronic eye conditions.